11th week of 2010 patent applcation highlights part 50 |
Patent application number | Title | Published |
20100069309 | Method for medical treatment utilizing glutathione - A method of treating a condition or conditions caused by damage to cells by a process of oxidative stress and glutathione depletion. In some exemplary embodiments, the condition or conditions may be treated by administering reduced L-glutathione to a patient through injection or intravenous infusion. In other exemplary embodiments, the condition or conditions may be treated by administering reduced glutathione monoethyl ester through injection or intravenous infusion. | 2010-03-18 |
20100069310 | GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZONITRILE DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE - Glucopyranosyl-substituted benzyl-benzonitrile derivatives of general formula (I) as defined according to claim | 2010-03-18 |
20100069311 | MEDICAMENT COMPRISING A REDUCING ALKYL-SUGAR MONOMER FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The invention relates to a medicament comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C | 2010-03-18 |
20100069312 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS FOR TREATING AUTOIMMUNE DISEASES - The invention provides prophylactic and therapeutic applications of select aminoalkyl glucosamine phosphate (AGP) compounds in autoimmune diseases. | 2010-03-18 |
20100069313 | NOVEL POWDERS BASED ON VEGETATION WATER FROM OLIVE OIL PRODUCTION - The present invention is directed a process for the manufacture of a powder comprising vegetation water rich in water-soluble polyphenols, especially rich in hydroxytyrosol, as well as to the powders themselves and dietary supplements, especially in form of tablets, food, feed and cosmetic preparations containing such powders. The process comprises the following steps: A) providing vegetation water (concentrate) containing water-soluble polyphenols; B) (optionally) modifying the water content of the vegetation water (concentrate); C) optionally centrifuging the vegetation water (concentrate) and separating the water-soluble part; D) spray-drying or granulating the (water-soluble part of the) vegetation water (concentrate), preferably in presence of an adjuvant; E) optionally washing the thus obtained powder comprising vegetation water rich in water-soluble polyphenols with an organic solvent. | 2010-03-18 |
20100069314 | PESTICIDAL COMPOSITIONS - Stabilized mixtures of pesticides are disclosed. | 2010-03-18 |
20100069315 | METHOD AND MEDICAMENT FOR TREATING OCULAR INFECTIONS - The invention relates to a method for treating ocular infections, by topical application twice a day in each eye to be treated, for less than four days, of a medicament essentially consisting of azithromycin in solution in a pharmaceutically acceptable vehicle of linear medium-chain fatty acid triglycerides, at the concentration of 1% to 2%. | 2010-03-18 |
20100069316 | TREATMENT FOR MULTIPLE MYELOMA - The present invention provides methods of treating a subject suffering from multiple myeloma comprising administering to the subject an effect amount of a compound according to Formula I: | 2010-03-18 |
20100069317 | CRYSTALLINE NEMORUBICIN HYDROCHLORIDE - This invention relates to a novel crystalline polymorphic form of nemorubicin hydrochloride dihydrate, useful for the preparation of pharmaceutical composition for the treatment of tumors. A process for preparing this novel polymorphic form, named form A, is within the scope of the present invention. | 2010-03-18 |
20100069318 | COMBINATION OF AN HDAC INHIBITOR AND AN ANTIMETABOLITE - The invention relates to a combination which comprises:
| 2010-03-18 |
20100069319 | Mercaptopurine derivatives and uses thereof - The invention provides novel mercaptopurine derivatives, e.g., S-allylthio-6-mercaptopurine and S-allylthio-6-mercaptopurine 9-riboside, as well as pharmaceutical compositions thereof. These compounds are highly efficient anti-proliferative agents, thus can be useful for treatment of various diseases or disorders, in particular, proliferative, inflammatory, skin and immune diseases or disorders. | 2010-03-18 |
20100069320 | SYNERGISM OF GOS AND POLYFRUCTOSE - The present invention relates to the filed of prebiotics. Provided are uses for compositions comprising synergistically effective amounts of polyfructose and galactooligosaccharides (GOS). | 2010-03-18 |
20100069321 | Biological Materials and Uses Thereof - The invention relates to the modification of proteins to improve their, biochemical, immunological or biophysical properties, in turn leading to such proteins having increased diagnostic, biotechnological or therapeutic benefit. In particular the invention relates to polysialylation of proteins or conjugates of proteins. There is also provided, nucleotide sequences and expression vectors encoding, host cells expressing, compositions comprising and uses of the polysialylated molecules of the invention. | 2010-03-18 |
20100069322 | INHIBITION OF CHOLERA TOXINS BY GALATOOLIGOSACCHARIDES (GOS) - The invention relates to nutritional and pharmaceutical compositions comprising non-digestible galactooligosaccharides (GOS) and uses thereof. In particular, it relates to the use of GOS species in preventing or treating disease caused by bacterial toxins. Provided is the use of GOS having a polymerization degree of 5 or higher, preferably 6 or higher, for the manufacture of a nutritional or pharmaceutical composition for the treatment or prevention of an acute or chronic disease associated with or caused by the adhesion and/or uptake of a cholera toxin family member. Also provided is a method for providing a GOS fraction capable of inhibiting cholera toxin (Ctx) binding to GM1 and fractions obtainable thereby. | 2010-03-18 |
20100069323 | COMPOSITION FOR APPLICATION TO SKIN OR MUCOSA - Disclosed is a composition for application to skin or mucosa comprising alginic acid and/or salts thereof, which has reduced cytotoxicity against a skin cell or mucosa cell and higher safety, the composition for application to skin or mucosa comprises an alginic acid and/or salts thereof that contains substantially no low-molecular-weight fraction having a molecular weight of 3,500 or less. | 2010-03-18 |
20100069324 | NANOPARTICLE OF GLUCIDAMIN FOR TREATING TUMOR AND PREPARATION METHOD THEREOF - A nanoparticle of glucidamin derived from organism for treating tumor and preparation method thereof, wherein the viscosity-average molecular weight of glucidamin is in the range of 1×10 | 2010-03-18 |
20100069325 | Pharmaceutical composition for treatment of chronic liver diseases and use thereof - A pharmaceutical composition for treatment of chronic liver diseases, the composition including at least cordyceps sinensis polysaccharide, amygdaloside, and gypenoside. The pharmaceutical composition slows down liver fibrosis, stops the development thereof, or reverses the same. A method of using the pharmaceutical composition for treatment of chronic liver diseases. | 2010-03-18 |
20100069326 | Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders - The invention is compositions and methods for treating vascular disorders and/or conditions that involve administering a first agent comprising triflusal (or a triflusal analog or derivative) in combination with at least one other active agent. | 2010-03-18 |
20100069327 | NUTRITIONAL PRODUCTS COMPRISING SACCHARIDE OLIGOMERS - Indigestible oligosaccharides having a molecular weight of 450 Da to 3700 Da are used for the improvement of insulin resistance, the prevention of post-prandial glycaemic dip, and/or the decrease of the post-prandial glucose response of a meal, which is consumed within 72 hours after the consumption of the first product. The oligo-saccharides are especially galacto-oligosaccharides, and are advantageously administered a few hours prior to having the meal. | 2010-03-18 |
20100069328 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER - The present invention is directed to a compound of formula I, | 2010-03-18 |
20100069329 | COSMETIC COMPOSITIONS COMPRISING HYDROLYSIS RESISTANT ORGANOMODIFIED DISILOXANE SURFACTANTS - Compositions comprising disiloxane surfactant compositions comprising a silicone composition comprising a silicone having the formula: | 2010-03-18 |
20100069330 | Pharmaceutical Compositions and Methods for Preparing and Using Lipophilic Organosulfur Cell Proliferation Inhibitors - Novel compositions of lipophilic organosulfur compounds, their preparation and use in methods for treating disease are described. Silicon confers lipophilicity that can enhance the penetration of the silicon derivative compounds across the gut wall, cell membranes and blood brain barrier, thus improving therapeutic properties including bioavailability, metabolism, and/or pharmacokinetics. The organosilyl group provides compounds having improved pharmacokinetics. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, polymorphic forms, crystalline forms or an amorphous form, pharmaceutical compositions and methods for treatment of diseases, maladies or conditions. Also disclosed are processes for making such compounds as well as intermediates useful in such processes. | 2010-03-18 |
20100069331 | TREATMENT OR PREVENTION OF CANCER AND PRECANCEROUS DISORDERS - The NSAID, sulindac and/or its metabolites and derivatives, in combination with an agent that generates or induces reactive oxygen species (ROS), significantly enhances the killing of abnormal cells but does not affect normal cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against the abnormal cells. | 2010-03-18 |
20100069332 | Lipids containing omega-3 and omega-6 fatty acids - A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes. | 2010-03-18 |
20100069333 | ALPHA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS - The invention provides α-mimetic structures and a chemical library relating thereto. Additionally, the invention provides methods wherein α-mimetic compounds are used to treat cancer stem cells. | 2010-03-18 |
20100069334 | Diagnostic method - A method for prognosing osteoporosis phenotypes or estimating osteoporosis quantitative traits comprising determining outcomes for selected SNP variables and clinical variables. Products and methods for genotyping multiple osteoporosis associated genetic variations. | 2010-03-18 |
20100069335 | Prevention and Treatment of Ophthalmic Complications of Diabetes - An method and formulation are provided for the prevention and treatment of adverse ocular conditions which are complications of diabetes. In one embodiment, the invention comprises administering to a person having diabetes, insulin resistance, or a risk factor for diabetes a formulation comprising a metal chelator and a transport enhancer. Most preferably, the metal chelator is EDTA or a salt of EDTA, and the transport enhancer is methylsulfonylmethane (MSM). The formulation may be in a form suitable for application to the eye itself, for example, in the form of eye drops. | 2010-03-18 |
20100069336 | HIGH PENETRATION PRODRUG COMPOSITIONS OF MUSTARDS AND MUSTARD-RELATED COMPOUNDS - The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of mustards and mustard-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. | 2010-03-18 |
20100069337 | BUTYRYLCHOLINESTERASE INHIBITORS - Butyrylcholinesterase inhibitors, their formulation, and their use primarily in the treatment of neurodegenerative diseases. These inhibitors generally are phosphates, phosphonates, phosphinates, and phosphoramidates. These inhibitors can be incorporated in pharmaceutical compositions and administered to a patient in therapeutically effective amounts to treat neurodegenerative diseases. | 2010-03-18 |
20100069338 | PHARMACEUTICAL COMPOSITIONS - The present invention provides a composition for topical administration to the skin for treating and/or preventing a dermatological condition involving an abnormal decrease in the cell-to-cell adhesion between epithelial cells comprising a zinc salt which is at least partially soluble in water and an acid, wherein the composition has a pH less than or equal to 6. The dermatological condition is generally selected from eczema, dermatitis, atopic eczema, atopic dermatitis, non-atopic eczema, non-atopic dermatitis, seborrheic eczema, irritant contact dermatitis, allergic contact dermatitis, pruritus and sensitive skin. A preferred composition comprises zinc lactate, lactic acid and has a pH of about 4.0 to 5.0. | 2010-03-18 |
20100069339 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY - There is provided a method of treatment of male sub-fertility by using a vitamin D compound. Compositions and uses are also provided. | 2010-03-18 |
20100069340 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR - This invention is directed to a pharmaceutical composition comprising an Src kinase inhibitor and an aromatase inhibitor, and to the use of a combination of an Src kinase inhibitor and an aromatase inhibitor in treating abnormal cell proliferation and abnormal angiogenesis associated with cancer, including breast cancer. | 2010-03-18 |
20100069341 | TETRAHYDRO-PYRANOPYRAZOLE CANNABINOID MODULATORS - This invention is directed to a tetrahydro-pyranopyrazole cannabinoid modulator compound of formula (I): | 2010-03-18 |
20100069342 | FORMOTEROL/STEROID BRONCHODILATING COMPOSITIONS AND METHODS OF USE THEREOF - Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided. | 2010-03-18 |
20100069343 | Methods of predicting steroid responsiveness with Il-1RII - Methods are provided for determining in vitro whether or not a patient will respond to steroid treatment based on the levels of interleukin-1 receptor type II (IL-1RII) in a sample of mononuclear immune cells obtained from the patient before steroid treatment and/or on the change in IL-1RII in the patient's mononuclear immune cells in response to an in vitro steroid challenge. | 2010-03-18 |
20100069344 | SMALL MOLECULE ANTAGONISTS OF BCL2 FAMILY PROTEINS - The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of Bcl-2 family proteins. In particular, the present invention provides gossypol compounds (e.g., isomers, enantiomers, racemic compounds, metabolites, derivatives, pharmaceutically acceptable salts, in combination with acids or bases, and the like) and methods of using these compounds as antagonists of the anti-apoptotic effects of Bcl-2 family member proteins (e.g., Bcl-2, Bcl-X | 2010-03-18 |
20100069345 | Lanthanide-porphyrin complexes as anti-tumor agents - The present invention relates to lanthanide porphyrin complexes and their uses as anti-tumor agents. The described complexes show promising cytotoxic properties toward cancer cells in both in vitro and in vivo studies. | 2010-03-18 |
20100069346 | New Azetidine Derivatives as Neurokinin Receptor Antagonists for the Treatment of Gastrointestinal Diseases - The application relates to new piperazine- or morpholine-substituted azetidine derivatives of formula I. These compounds are antagonists at the neurokinin receptor and can be used for the treatment of gastrointestinal diseases. The application also relates to processes for the preparation of the compounds and to intermediates in said preparation. | 2010-03-18 |
20100069347 | HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS - This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts thereof, wherein R | 2010-03-18 |
20100069348 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - Disclosed herein are cannabinoid receptor ligands of formula (I) | 2010-03-18 |
20100069349 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - Disclosed herein are cannabinoid receptor ligands of formula (I) | 2010-03-18 |
20100069350 | New Pyridine Analogues III - The present invention relates to certain new pyridin analogues of Formula (I), to processes for preparing such compounds, to their utility as P2Y | 2010-03-18 |
20100069351 | SPIRO COMPOUND AND USE THEREOF - The present invention aims to provide a novel SCD inhibitor. | 2010-03-18 |
20100069352 | 5- [4-(AZETIDIN-3-YLOXY)-PHENYL]-2-PHENYL-5H-THIAZOLO[5,4-C] PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS - The present invention relates to a melanin concentrating hormone antagonist compound of formula I: wherein “ - - - ” is absent or is optionally a bond; q is 1 or 2; R | 2010-03-18 |
20100069353 | INHIBITORS OF HIV REPLICATION - The present invention relates to compounds of formula (I) wherein R | 2010-03-18 |
20100069354 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE - The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them. | 2010-03-18 |
20100069355 | Analogs of Indole-3-Carbinol and Their Use as Agents Against Infection - Compounds useful as antibacterial agents are provided. The compounds are analogs of indole-3-carbinol and have a backbone selected from dihydroindolo[2,3-b]carbazole, 2,2′-diindolylmethane, 2′,3-diindolylmethane, and 3,3′-diindolylmethane. The compounds are useful therapeutic and prophylactic treatment of bacterial infections in mammals. Methods of synthesis of the compounds are provided, as are pharmaceutical compositions containing the compounds. | 2010-03-18 |
20100069356 | DIBENZOTHIAZEPINE MODULATORS OF DOPAMINE, ALPHA ADRENERGIC, AND SEROTONIN RECEPTORS - The present invention relates to new dibenzothiazepine modulators of D1 receptors, D2 receptors, alpha-1 adrenergic receptors, alpha-2 adrenergic receptors, H1 receptors, 5-HT1A receptors, and/or 5-HT2 receptors, pharmaceutical compositions thereof, and methods of use thereof. | 2010-03-18 |
20100069357 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR). | 2010-03-18 |
20100069358 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE - The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them. | 2010-03-18 |
20100069359 | CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS - Compounds of formula I: | 2010-03-18 |
20100069360 | ORGANIC COMPOUNDS - A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: | 2010-03-18 |
20100069361 | Fused Thiazole Derivatives as Kinase Inhibitors - A series of 5,5-dimethyl-5,6-dihydro-1,3-benzothiazol-7(4H)-one and 7,7-dimethyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-4-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted benzofused morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I). | 2010-03-18 |
20100069362 | Thienopyrimidone compound - The present invention relates to a compound represented by the formula: | 2010-03-18 |
20100069363 | SUBSTITUTED 4-AMINO-3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF - The present application relates to novel substituted 4-amino-3,5-dicyano-2-thiopyridine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders. | 2010-03-18 |
20100069364 | SUBSTITUTED PYRAZOLINE COMPOUNDS WITH ACAT INHIBITION ACTIVITY, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia. | 2010-03-18 |
20100069365 | Diazepane-acetamide derivatives as selective 11B-HSD1 inhibitors - The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions. | 2010-03-18 |
20100069366 | ANTIBACTERIAL QUINOLINE DERIVATIVES - The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or Formula (Ib): | 2010-03-18 |
20100069367 | LXR and FXR Modulators - Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R | 2010-03-18 |
20100069368 | Organic Compounds and Their Uses - The present disclosure relates to compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders; specifically relating to compounds of formula I: | 2010-03-18 |
20100069369 | Kinase Inhibitors And Their Uses - The present disclosure provides compounds that inhibit protein kinases, such as JAK, Axl, or Syk kinases, compositions comprising the compounds and methods of using the compounds to inhibit protein kinase and treat and/or prevent diseases associated with inappropriate kinase activity. The compounds of the present invention are according to structural formula (I): | 2010-03-18 |
20100069370 | COMPOUNDS, COMPOSITIONS AND METHODS - Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 2010-03-18 |
20100069371 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS - Compounds having the formula | 2010-03-18 |
20100069372 | COMPOSITIONS AND METHODS FOR MODULATING POLY(ADP-RIBOSE) POLYMERASE ACTIVITY - The present invention is based, in part, on assays we conducted that revealed compounds that modulate (e.g., inhibit) PARP-1 and are therefore useful in treating or preventing diseases characterized by abnormal PARP-1 activity (e.g., undesirable PARP-1 activity). | 2010-03-18 |
20100069373 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION - This invention relates to novel lactams of Formula (I): | 2010-03-18 |
20100069374 | Tricyclic benzopyrane compound - This invention relates to benzopyran derivatives of formula (I) or (II), or pharmaceutically acceptable salts thereof | 2010-03-18 |
20100069375 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses - The present invention relates to indolone-acetamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as for the treatment of epilepsy, epileptogenesis, seizure disorders and convulsion. | 2010-03-18 |
20100069376 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS - The invention relates to novel chimeric antibiotics of formula I | 2010-03-18 |
20100069378 | SUBSTITUTED INDANYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention refers to new indanyl sulphonamide compounds with general formula (I), as well as to their preparation procedure, their application as medicine and the pharmaceuticals composition which they are made up of. The new compounds of formula (I) show affinity for 5-HT | 2010-03-18 |
20100069379 | Bicyclic androgen and progesterone receptor modulator compounds and methods - The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and antagonists for AR and PR. Also provided are methods of making such compounds and pharmaceutical compositions, as well as critical intermediates used in their synthesis. | 2010-03-18 |
20100069380 | HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF - Provided herein are compounds that modulate the activity of a bacterial peptidyl tRNA hydrolase, including compositions and dosage forms comprising the compounds. Further provided herein are methods for screening and identifying compounds that modulate the activity of a bacterial peptidyl tRNA hydrolase. In particular, provided herein are assays for the identification of compounds that inhibit or reduce the activity of a bacterial peptidyl tRNA hydrolase. The methods provided herein provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads useful for preventing, treating, and managing a bacterial infection or one or more symptoms thereof. Further provided herein are methods for preventing or inhibiting bacterial proliferation as well as methods for preventing, treating, and/or managing a bacterial infection using such compounds and compositions. | 2010-03-18 |
20100069381 | GSK-3BETAINHIBITOR - For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I): | 2010-03-18 |
20100069382 | Agent for prophylaxis or treatment of alcohol dependence or drug dependence - The present invention provides an agent for the prophylaxis or treatment of substance abuse and dependence, which contains a compound of the formula (I) represented by (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, or a pharmaceutically acceptable salt thereof as an active ingredient. | 2010-03-18 |
20100069383 | COMPOUNDS AND THERAPEUTICAL USE THEREOF - Disclosed are 4-arylamino-quinazolines and analogs thereof that are effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. | 2010-03-18 |
20100069384 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY - The present invention relates to derivatives of 5-alkyloxy-indolin-2-one, their method of production and their therapeutic applications. These novel derivatives have affinity and selectivity for the V | 2010-03-18 |
20100069385 | LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS - The present invention is directed to liquid formulations of inhibitors of phospholipase enzymes, such as cytosolic PLA2, compositions containing the same and processes for manufacture thereof. | 2010-03-18 |
20100069386 | Modulators of Hedgehog Signaling Pathways, Compositions and Uses Related Thereto - The present invention makes available methods and reagents for inhibiting aberrant growth states resulting form hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. Such methods and reagents may also inhibit the hedgehog pathway in normal cells, e.g., where normal levels of hedgehog signalling are unwanted. | 2010-03-18 |
20100069387 | IKK Inhibitors for the Treatment of Endometriosis - This invention relates to a method of treating and/or preventing endometriosis comprising administering an IKK inhibitor. The IKK inhibitor can also be administered combined with a hormonal suppressor. The invention further relates to the treatment of endometriosis-related infertility. | 2010-03-18 |
20100069388 | N-HYDROXYACRYLAMIDE COMPOUNDS - A compound having the following formula (I): wherein —R | 2010-03-18 |
20100069389 | NOVEL FORMS OF REBOXETINE - The invention relates to novel crystalline forms of (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine hydrochloride. In various embodiments, the novel crystalline forms may be substantially enantiopure. The preparation and characterization of the novel crystalline forms of (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine hydrochloride is also described. The invention also relates to pharmaceutical compositions containing novel crystalline forms of (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine hydrochloride, which are useful to treat and/or prevent various conditions such as nervous system and pain disorders. | 2010-03-18 |
20100069390 | Method of treatment of attention deficit/hyperactivity disorder (ADHD) - The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity. | 2010-03-18 |
20100069391 | Novel sEH Inhibitors and Their Use - The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. | 2010-03-18 |
20100069392 | Combination of HMG-COA Reductase Inhibitors with Phosphodiesterase 4 Inhibitors for the Treatment of Inflammatory Pulmonary Disease - The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease. | 2010-03-18 |
20100069393 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME - The present invention relates generally to therapeutic agents, formulations comprising them and their use in the treatment, amelioration and/or prophylaxis of glioma brain tumours and related conditions. The therapeutic agent comprises two fused 6-membered rings with at least a nitrogen at position 1 and a hydroxyl at position 8. | 2010-03-18 |
20100069394 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS - The present invention relates to 4-aryl-6-piperazin-1-yl-3-substituted-pyridazines that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects. | 2010-03-18 |
20100069395 | Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors - Compounds of formula | 2010-03-18 |
20100069396 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES - Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 4-amino-3-imidazoyl-pyrazolo[3,4-d]pyrimidine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists. | 2010-03-18 |
20100069398 | Combination therapy - The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour or a leukaemia, which comprises the administration of ZD6474 in combination with imatinib; to a pharmaceutical composition comprising ZD6474 and imatinib; to a combination product comprising ZD6474 and imatinib for use in a method of treatment of a human or animal body by therapy; to a kit comprising ZD6474 and imatinib; to the use of ZD6474 and imatinib in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation. | 2010-03-18 |
20100069399 | ARYLPIPERAZINE MODULATORS OF D2 RECEPTORS, 5-HT1A RECEPTORS, AND/OR 5-HT2A RECEPTORS - The present invention relates to new arylpiperazine modulators of D2 receptors, 5-HT1A receptors, and/or 5-HT2A receptors, pharmaceutical compositions thereof, and methods of use thereof. | 2010-03-18 |
20100069400 | METHODS FOR TREATING INFLAMMATION AND RELATED CONDITIONS - A method for treating an inflammatory condition or immune disorder comprises administering to a subject having such a condition or disorder a therapeutically effective amount of at least one compound selected from irindalone, physiologically active enantiomers thereof, and pharmaceutically acceptable salts thereof. The invention further provides a method for elevating levels of anti-inflammatory cytokines such as IL-10 and IL-13 while inhibiting expression of pro-inflammatory cytokines. A pharmaceutical composition, useful for example in topical treatment of psoriasis, comprises a therapeutically effective amount of at least one compound selected from irindalone, physiologically active enantiomers thereof, and pharmaceutically acceptable salts thereof, in a vehicle comprising at least one pharmaceutically acceptable excipient, the vehicle being adapted for topical administration to skin of a subject. | 2010-03-18 |
20100069401 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS - A catecholamine or related compound of formula (I) having (S)-configuration at β-carbon and having a lipophilicity greater than (S)-noradrenalme, a physiologically tolerated salt thereof, a prodrug thereof, a physiologically functional derivative thereof or any mixture thereof is useful as an anti-angiogemc agent A catecholamine or related compound of formula (II) in which a β-hydroxy group has been modified is also anti-angiogemc | 2010-03-18 |
20100069402 | Treatment of Behavioral Disorders - The present invention relates to a method for treating a behavior disorder comprising the administration of a therapeutically effective amount of antihistamine, such as cetirizine, fexofenadine; loratadine, and desloratadine. The behavioral disorders may include ADHD, anxiety, depression, and autism. The method may include the administration of the antihistamine in combination with a stimulant medication, such as methylphenidate, thereby to achieve a synergistic effect. In any event, the amount of antihistamine and/or stimulant is effective to downregulate neurotrophic factors such as nerve growth factor or CD40. The invention is also directed to a method of preventing the onset of behavior disorders in patients presenting with symptoms of allergic rhinitis. | 2010-03-18 |
20100069403 | Methods for preventing or treating cardiac arrhythmia - Disclosed are methods of preventing or treating cardiac arrhythmia comprising administering to a mammal in need thereof, such as a human, an effective amount of vanoxerine (GBR 12909) or a pharmaceutically acceptable salt, derivative or metabolite thereof. | 2010-03-18 |
20100069404 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS - The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly reduced bones mass, osteoporosis, osteopenia, or reduced muscle mass or strength, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof. X-17142. | 2010-03-18 |
20100069405 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS - The present invention is directed to compounds and compositions for the treatment of neurological diseases that cause neurogenic and neuropathic pain, inflammatory diseases, renal ischaemia, cardiovascular disease and other pathologies caused by the presence of endogenous cannabinoids and or other substrates resulting from the metabolic activities of fatty acid amido hydrolase (FAAH). These compounds are represented by the formula (I): | 2010-03-18 |
20100069406 | ASPARTYL PROTEASE INHIBITORS - Disclosed are compounds of formula I (Chemical formula should be inserted here as it appears on abstract in paper form) Formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein R | 2010-03-18 |
20100069407 | CXCR2 inhibitors - The present invention relates to compounds of formula (I) and the use of these compounds as pharmaceuticals, e.g. in preventing or treating a CXCR2 receptor mediated condition or disease. | 2010-03-18 |
20100069408 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition - The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. | 2010-03-18 |
20100069409 | "NOVEL COMPOUNDS" - Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, and 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(M)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors. | 2010-03-18 |
20100069410 | ACYCLOVIR FORMULATIONS - The present invention relates to acyclovir formulations having improved bioavailability resulting in better efficacy and/or requiring less frequent administration. | 2010-03-18 |